Lenzings, Heiligenkreuz

Lenzing's Heiligenkreuz Fork: Binding Bids or a Shutdown by Early 2027

Published on 11/18/2026 at 15:32 | Editorial boerse-global.de
Lenzing reviews nonbinding offers for Heiligenkreuz, with a viable sale decision due by end-2026 or the plant closes after Q1 2027.
Lenzing's Heiligenkreuz Fork: Binding Bids or a Shutdown by Early 2027 Illustration mit AI erstellt.

Lenzing has two clocks running at once, and they tick at different speeds. One measures a EUR 50 million expansion of its specialty-fibre and nonwovens footprint; the other counts down to a decision on whether the Heiligenkreuz plant is sold or shuttered. Investors who treat both as the same kind of commitment are misreading the situation.

The equity moved lower on Tuesday, slipping 3.4% as European markets retreated after Washington tightened restrictions on AI-chip sales to China. That backdrop says little about Lenzing itself. The more instructive signal came on 12 November, when the company confirmed it had received several nonbinding purchase offers for Heiligenkreuz and was reviewing them.

A deadline, not a deal

Management aims to establish by the end of 2026 whether an economically viable sale is achievable. Failing that, the site is slated to close at the end of the first quarter of 2027. The existence of interested parties is therefore not the test — the quality of their offers is. A workable agreement would open an alternative path to the planned closure, though any financial benefit would depend entirely on the terms attached to it.

The opposite risk is just as real: a review that produces no viable buyer. Multiple expressions of interest do not by themselves raise the odds of a completed transaction, and if this route dead-ends, the announced closure remains the default.

Should investors sell immediately? Or is it worth buying Lenzing?

Where the money is actually going

Separately, Lenzing has committed EUR 27 million to specialty-fibre capacity for nonwoven applications at its Mobile, Alabama site. The outlay sits inside a EUR 50 million programme for the nonwovens business, of which EUR 23 million is earmarked for the previously announced expansion at the Austrian Lenzing site. Announced spending demonstrates planned capacity growth; whether it translates into improved economics is a separate question that a positive assessment would have to weigh alongside the Heiligenkreuz outcome.

The earnings picture behind the headlines

The operational backdrop is mixed. Lenzing generated adjusted EBITDA of EUR 353.0 million in the first nine months of 2026, while posting a loss after tax of EUR 130.3 million. Reported EBITDA came in at EUR 316.4 million, dented by restructuring effects of EUR 36.6 million, according to the company. For the full year 2026, management guides adjusted EBITDA to a range of EUR 430 million to EUR 460 million.

Deutsche Bank Research weighed in on 9 November, lifting its price target to EUR 14.30 from EUR 12.70 while keeping a "Hold" rating, with Lars vom Cleff attached to the call.

Lenzing at a turning point? This analysis reveals what investors need to know now.

The stock's Tuesday decline of 3.4% contrasts with a separate 2.1% fall noted in earlier trading — two sessions, two different readings, both set against the same unresolved question. What matters for valuation is not how many suitors have come forward for Heiligenkreuz but what binding position Lenzing reaches by the end of 2026. Until then, a sale remains a scenario rather than a result, and the investment programme a statement of direction rather than proof of returns.

Ad

Lenzing Stock: New Analysis - 18 November

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...

Disclaimer...
en | AT0000644505 | LENZINGS | boerse | 70531242 |